Patrick (Paddy) Mark is Professor of Nephrology and Honorary Consultant Nephrologist at the Glasgow Renal and Transplant Unit based at the Queen Elizabeth University Hospital Glasgow. He was appointed as Clinical Senior Lecturer in 2011 following clinical training in Medicine and Nephrology combined with a Clinical Lecturer post between 2006-2011. He was promoted to Reader in 2015 and to Professor in 2018. He leads the United Kingdom Cardio-Renal Clinical Study Group, as part of the United Kingdom Kidney Research Consortium. He is the Chief Scientist Office Scotland Clinical Lead for Renal Research. His PhD, awarded the Bellahouston Medal for outstanding thesis by medical graduate, was funded by a British Heart Foundation Junior Clinical Fellowship. He graduated in Medicine in 1999 as Brunton Medallist awarded to the highest achieving student that year.
Dr. Lisa M. Guay-Woodford is the McGehee Joyce Professor of Pediatrics at the Children’s National Medical Center (CNMC), a pediatric nephrologist, and an internationally-recognized investigator whose research focuses on identifying clinical and genetic factors involved in the pathogenesis of inherited renal disorders, most notably autosomal recessive polycystic kidney disease (ARPKD). Her laboratory has identified the disease-causing genes in several mouse models of recessive polycystic kidney disease and her group participated in the identification of the human ARPKD gene as part of the ARPKD Consortium. In addition, her laboratory was the first to identify a candidate modifier gene for recessive polycystic kidney disease. Dr. Guay-Woodford has over 140 peer-reviewed publications based on research performed in her own laboratory or as a member of several national and international consortia. She has directed the NIDDK P30-funded Hepato-Renal Fibrocystic Disease Research and Translational Core Center, initially established at the University of Alabama at Birmingham in 2005, and continues to serve as co-Director since moving to CNMC in 2012. Her research program has been funded by the NIH, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, and the Polycystic Kidney Disease Foundation. In 2009, Dr. Guay-Woodford was awarded the Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease, given by the PKD Foundation and the International Society of Nephrology.
In addition to her investigative work, Dr. Guay-Woodford has established and serves as Director of the CNMC Inherited Renal Disorders Program. She is the Director of the Center for Translational Science, as well as Director of the Clinical and Translational Science Institute at Children’s National Medical Center (CTSI-CN), which is funded by the NIH CTSA program. She serves on several editorial boards for journals in her field. She has been a permanent member and Chair of the NIH Cellular and Molecular Biology of the Kidney Study Section. She is the Past President of the Society for Pediatric Research and Councilor for the International Pediatric Nephrology Association. She has served as a Board of Trustee member for the Polycystic Kidney Disease Foundation as well as the Association of Clinical and Translational Science. She currently serves as a member of the National Institute of Diabetes and Digestive and Kidney Diseases Advisory Council.
Raelene Pickering is an experienced molecular and cell biologist. She obtained her PhD in Immunology at Monash University investigating the modulation of the immune response to a plant-made vaccine. During her PhD she gained a broad range of skills in molecular biology, immunology as well as experience with animal studies in mice and baboons. After completion of her PhD she changed fields accepting a post-doc position in Merlin Thomas’ laboratory at BakerIDI to begin research into Diabetic Complications. Here she gained experience with RAAS signalling and diabetic mouse models. For the past 8 years, most of her research has been focused on Angiotensin II signalling through the Angiotensin II type 1 receptor and Receptor for Advanced Glycation End products (RAGE) in atherosclerosis. Her recent work has described a new Angiotensin II signalling mechanism. Here she was able to demonstrate that the RAGE and the angiotensin II type 1 receptors are co-located, that the RAGE tail is transactivated leading to inflammation and that this signalling can be blocked. She is also interested in the role of this signalling pathway and RAGE in other diseases.